A Partially Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 730460 Administered as Tablets to Healthy Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Bioavailability Comparison of BI 730460 as Tablet With and Without Food
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs BI 730460 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 26 Mar 2019 Status changed from recruiting to completed.
- 04 Mar 2019 Planned End Date changed from 16 Apr 2019 to 10 May 2019.
- 04 Mar 2019 Planned primary completion date changed from 16 Apr 2019 to 10 May 2019.